Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phibro Animal Health (PAHC) Cash & Equivalents: 2012-2025

Historic Cash & Equivalents for Phibro Animal Health (PAHC) over the last 14 years, with Jun 2025 value amounting to $68.0 million.

  • Phibro Animal Health's Cash & Equivalents rose 40.38% to $72.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.8 million, marking a year-over-year increase of 40.38%. This contributed to the annual value of $68.0 million for FY2025, which is 3.65% down from last year.
  • Latest data reveals that Phibro Animal Health reported Cash & Equivalents of $68.0 million as of FY2025, which was down 3.65% from $70.6 million recorded in FY2024.
  • Phibro Animal Health's 5-year Cash & Equivalents high stood at $74.2 million for FY2022, and its period low was $41.3 million during FY2023.
  • For the 3-year period, Phibro Animal Health's Cash & Equivalents averaged around $60.0 million, with its median value being $68.0 million (2025).
  • As far as peak fluctuations go, Phibro Animal Health's Cash & Equivalents tumbled by 44.40% in 2023, and later skyrocketed by 71.05% in 2024.
  • Phibro Animal Health's Cash & Equivalents (MRY) stood at $50.2 million in 2021, then soared by 47.87% to $74.2 million in 2022, then crashed by 44.40% to $41.3 million in 2023, then skyrocketed by 71.05% to $70.6 million in 2024, then dropped by 3.65% to $68.0 million in 2025.
  • Its Cash & Equivalents was $68.0 million in FY2025, compared to $70.6 million in FY2024 and $41.3 million in FY2023.